Li Kang Biomedical Co., Ltd. (TPEX:6242)

Li Kang Biomedical Revenue

Li Kang Biomedical had revenue of 121.56M TWD in the quarter ending March 31, 2026, a decrease of -9.82%. This brings the company's revenue in the last twelve months to 575.98M, down -0.19% year-over-year. In the year 2025, Li Kang Biomedical had annual revenue of 589.21M with 4.19% growth.

• Revenue (ttm): 575.98M
• Revenue Growth: -0.19%
• P/S Ratio: 2.08
• Revenue / Employee: 4.72M
• Employees: 122
• Market Cap: 1.20B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	589.21M	23.69M	4.19%
Dec 31, 2024	565.52M	-63.86M	-10.15%
Dec 31, 2023	629.38M	-54.87M	-8.02%
Dec 31, 2022	684.25M	297.28M	76.82%
Dec 31, 2021	386.97M	-69.75M	-15.27%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 19, 2026

Data Sources Report a data error